Quarterly report pursuant to Section 13 or 15(d)

Note 9 - Related party transactions (Details Textual)

v3.24.2.u1
Note 9 - Related party transactions (Details Textual) - USD ($)
 6 Months Ended 32 Months Ended
Jun. 03, 2024
Jan. 31, 2024
Sep. 06, 2023
Nov. 04, 2021
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Dec. 31, 2023
Aug. 10, 2023
Schedule of Equity Method Investments [Line Items]                  
Financing costs including underwriting costs, professional fees and recognition of deferred financing costs $ 408,000,000 $ 1,400,000              
Underwriting costs (as percent) 7.00%                
Common Stock, Shares Outstanding         18,109,393   18,109,393 7,942,363  
Accrued liabilities         $ 5,196,000   $ 5,196,000 $ 8,829,000  
Accounts payable         7,111,000   7,111,000 3,492,000  
Public Offering [Member]                  
Schedule of Equity Method Investments [Line Items]                  
Common shares issued (in shares)   5,649,122              
Private Placement [Member]                  
Schedule of Equity Method Investments [Line Items]                  
Warrants to purchase common shares, exchange price $ 1.44                
Warrants to purchase common shares, number of warrants 192,750                
Over-Allotment Option [Member]                  
Schedule of Equity Method Investments [Line Items]                  
Common shares issued upon exercise of stock options   $ 736,842              
Common Shares [Member] | Warrant [Member]                  
Schedule of Equity Method Investments [Line Items]                  
Common warrants offering price   $ 1.71              
Supply Agreement [Member]                  
Schedule of Equity Method Investments [Line Items]                  
Expenses         0 $ 1,500,000 7,100,000    
Payment of supply costs             7,100,000    
Accrued liabilities         0   0 0  
Accounts payable         0   $ 0 $ 2,600,000  
Hanmi Licensing Agreement [Member]                  
Schedule of Equity Method Investments [Line Items]                  
License Fee, Total       $ 12,500,000          
Payments for License Fee       5,000,000          
Stock Issued During Period, Value, Licensing Fee       $ 7,500,000          
Hanmi Pharmaceuticals Co., Ltd. [Member]                  
Schedule of Equity Method Investments [Line Items]                  
Number of common shares held       215,703          
Future milestone payments       $ 407,500,000          
Proceeds from Issuance of Common Stock     $ 3,000,000            
Underwriting costs (as percent)   7.00%              
Professional Fees   $ 400,000              
Warrants to purchase common shares, exchange price   $ 1.71              
Investment Owned, Balance, Shares       215,703          
Payment of supply costs         $ 2,600,000 $ 3,100,000      
Hanmi Pharmaceuticals Co., Ltd. [Member] | Public Offering [Member]                  
Schedule of Equity Method Investments [Line Items]                  
Proceeds from Issuance of Common Stock   $ 9,700,000              
Premium share price (as a percent)   11.00%              
Hanmi Pharmaceuticals Co., Ltd. [Member] | Private Placement [Member]                  
Schedule of Equity Method Investments [Line Items]                  
Proceeds from Issuance of Common Stock   $ 4,000,000              
Common shares issued (in shares)   2,105,263              
Shares Issued, Price Per Share   $ 1.9              
Hanmi Pharmaceuticals Co., Ltd. [Member] | Common Shares [Member]                  
Schedule of Equity Method Investments [Line Items]                  
Number of shares sold     668,449            
Maximum [Member] | Hanmi Pharmaceuticals Co., Ltd. [Member]                  
Schedule of Equity Method Investments [Line Items]                  
Investment for ownership interest                 $ 7,000,000
Percentage of investment                 19.99%